Biologic questions for your doctor

Patients in Lagos, London, Mumbai, and everywhere else ask the same question: which biologic should I request? IBDPal cannot answer that for you online. Drug choice belongs to you and your local IBD team, based on your disease, history, infection risk, and what is actually available where you live. This guide gives country-neutral questions and vocabulary so you can partner in that conversation. It is educational only and does not recommend starting, stopping, or switching any medicine.

Why no website can pick your biologic

Biologics and advanced small molecules are not interchangeable pills. Anti-TNF drugs, integrin inhibitors, IL-12/23 blockers, and JAK inhibitors work on different immune pathways. What helped a friend in another country may not fit your disease location, prior failures, pregnancy plans, or local formulary.

Social media threads often name brand favorites. Clinicians instead match class to inflammation pattern, strictures, fistulas, extraintestinal symptoms, and monitoring capacity at your hospital. Your job is not to arrive with a demanded drug name but to understand why a class is proposed and what success looks like.

If you read U.S.-centric articles about prior authorization, translate the clinical parts (questions, monitoring, side effects) and ignore payer steps that do not apply locally. Our biologic access outside the U.S. guide covers formulary and denial topics for international readers.

What your gastroenterologist weighs

Disease type and extent matter. Ulcerative colitis limited to the left colon may follow different escalation paths than Crohn's with small-bowel strictures or perianal disease. Prior colonoscopy, MRI, or calprotectin trends help your team see whether inflammation is deep or mainly symptomatic.

Treatment history is central. Failure or intolerance of mesalamine, thiopurines, methotrexate, or steroids shapes which biologic class is next. Some pathways avoid repeating the same target after primary non-response.

Infection and vaccine status affect safety. Tuberculosis screening, hepatitis history, and live vaccine timing are standard before many biologics worldwide. Pregnancy plans, surgery dates, and joint or skin manifestations also steer choice.

Access is part of medicine, not a separate conversation. Ask early which agents your hospital stocks, whether infusion chairs exist, and whether home injection training is available. A perfect-on-paper drug helps no one if it cannot be delivered locally.

Generic names worth knowing

Brand names differ by country. Carry generic (INN) names on your medication list so any clinic understands your history. Examples patients often discuss with their teams include infliximab and adalimumab (anti-TNF), vedolizumab (integrin), ustekinumab (IL-12/23), risankizumab (IL-23), and tofacitinib or upadacitinib (JAK inhibitors).

Biosimilars use the same generic stem as reference biologics with a manufacturer suffix. Switching between biosimilar and reference product may be required by cost or policy. Ask how your team monitors response after any switch.

Write both generic and local brand on a one-page summary. Photograph your pens or infusion schedule. Translators at embassy clinics or telehealth visits rely on accurate drug names, not marketing labels alone.

Questions to bring to your appointment

Why is this class a fit for my disease type and severity right now? What alternatives did you consider and rule out?

How will we know it is working, and on what timeline? Will we repeat colonoscopy, calprotectin, CRP, or symptom scores at set intervals?

What monitoring labs or tests do I need before and during therapy? Which infection symptoms should trigger a same-day call?

Infusion or injection: who teaches me, where do doses happen, and what are missed-dose rules if travel or stock delays occur?

How does this interact with pregnancy plans, surgery, other autoimmune conditions, or vaccines I still need?

If this fails or causes side effects, what is our next step and how long do we wait before switching?

What does this cost locally, and who in your office helps with approvals or patient assistance if I cannot pay out of pocket?

When you are switching or starting after a failure

Secondary loss of response is common on long-term biologics. Drug levels, antibodies, and adherence review precede switching. Do not stop doses without a taper or replacement plan; rebound flares are real.

Bring a timeline of prior drugs, dates stopped, and why (side effect, non-response, access gap). Gaps from insurance or import delays should be documented; they affect how aggressively your team re-escalates.

Ask whether a washout period is needed between classes and how flare symptoms will be bridged with steroids or other short-term tools.

Tracking symptoms between visits

Week-by-week logs beat memory at short appointments. Note stool frequency, blood, urgency, pain, fatigue, joint flares, and mood. IBDPal or a simple notebook works.

Photograph rashes or mouth ulcers if extraintestinal symptoms appear. They may influence class choice even when gut symptoms seem stable.

Share logs before visits through portal upload or printed PDF so your clinician sees trends, not only how you feel on appointment day.

Practical tips

• Print generic drug names alongside local brands on your medication card.
• Ask for a written induction and maintenance schedule before your first dose.
• Request a clinic contact for fever or infection symptoms on immunosuppression.
• Bring prior endoscopy reports when seeing a new IBD specialist.
• If access blocks your prescribed drug, ask the same questions about the next available agent.

Common questions

Should I ask for the newest biologic?

Ask why any proposed drug fits your case. Newer is not automatically better for every patient or budget.

Can I demand a specific brand I saw online?

Share what you read, but expect your clinician to explain local availability, evidence, and safety for you.

What if only one biologic is available locally?

Focus questions on monitoring, response timelines, and backup plans if it fails or is denied.

Related resources

• Biologic access outside the U.S.
• Biologics overview
• Foundation medication guide
• Understanding biologics article
• IBD care outside the United States
• Doctor visit prep

Educational only. Not medical advice. Work with your IBD care team.

Read the full interactive version on ibdpal.org.